Risk Assessment of Failures in Generic Drug Development and Approval Procedure under Competitive Generic Drug Therapy and Patent Challenge Exclusivities Provided by the United States Food and Drug Administration

1. O’Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021; 336:144-158.10.1016/j.jconrel.2021.06.01734126170Search in Google Scholar

2. Chazin H, Woo J, Han J, Grosser S, Luan J. FDA’s Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles. Ther Innov Regul Sci. 2020;54(4):758-763.10.1007/s43441-019-00016-232557293Search in Google Scholar

3. Woo J, Luan JJ, Li Z, Grosser S, Peters J, Chazin H. Abbreviated New Drug Applications: Generic Drug User Fee Amendments Act Analysis of Application Quality Metrics. Ther Innov Regul Sci. 2019;53(5):696-700.10.1177/216847901880619230360656Search in Google Scholar

4. Food and Drug Administration. Silver spring: The competitive Generic Therapy; [updated 2021 Aug 06; cited 2021 Aug 12]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapiesSearch in Google Scholar

5. Food and Drug Administration. Silver spring: Patent Challenge exclusivity; [updated 2021 Aug 02; cited 2021 Aug 10]. Available from: https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/small-business-assistance-180-day-generic-drug-exclusivitySearch in Google Scholar

6. Gurgula O. Strategic Patenting by Pharmaceutical Companies–Should Competition Law Intervene?. IIC-International Review of Intellectual Property and Competition Law. 2020;51(9):1062-85.10.1007/s40319-020-00985-0759214033132411Search in Google Scholar

7. Sahragardjoonegani B, Beall RF, Kesselheim AS, Hollis A. Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. Journal of pharmaceutical policy and practice. 2021;14(1):1-8.10.1186/s40545-020-00282-8778060733397471Search in Google Scholar

8. Holman CM, Minssen T, Solovy EM. Patentability standards for follow-on pharmaceutical innovation. Biotechnology Law Report. 2018;37(3):131-61.10.1089/blr.2018.29073.cmhSearch in Google Scholar

9. Hering S, Loretz B, Friedli T, Lehr CM, Stieneker F. Can lifecycle management safeguard innovation in the pharmaceutical industry? Drug Discov Today. 2018;23(12):1962-1973.10.1016/j.drudis.2018.10.00830342247Search in Google Scholar

10. Xie J. Horizontal Shareholdings and Paragraph IV Generic Entry in the U.S. Pharmaceutical Industry. The Antitrust Bulletin. 2021;66(1):100-112.10.1177/0003603X20985797Search in Google Scholar

11. Beall RF, Ronksley PE, Wick J, Darrow JJ, Sarpatwari A, Kesselheim AS. Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clin Pharmacol Ther. 2020;108(6):1308-1314.10.1002/cpt.198132621540Search in Google Scholar

12. Gupta R, Shah ND, Ross JS. Generic drugs in the United States: policies to address pricing and competition. Clinical Pharmacology & Therapeutics. 2019;105(2):329-37.10.1002/cpt.1314635535630471089Search in Google Scholar

13. Olson LM, Wendling BW. Estimating the causal effect of entry on generic drug prices using Hatch–Waxman exclusivity. Review of Industrial Organization. 2018; 53(1):139-72.10.1007/s11151-018-9627-ySearch in Google Scholar

14. Bernstein JJJ, Holt GB, Bernstein J. Price dispersion of generic medications. PLoS One. 2019; 14(11): e0225280.10.1371/journal.pone.0225280686093231738807Search in Google Scholar

15. Food and Drug Administration. Silver spring: Total Generic’s approved;[updated 2021 Sep 23; cited 2021 Aug 05]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/Search in Google Scholar

16. Food and Drug Administration. Silver spring: First generic drugs;[updated 2021 Sep 28; cited 2021 Aug 07]. Available from: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvalsSearch in Google Scholar

17. Food and Drug Administration. Silver spring: Patent Challenge exclusivity; [updated 2021 Aug 02; cited 2021 Aug 10]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitionsSearch in Google Scholar

18. Food and Drug Administration. Silver spring: The competitive Generic Therapy; [updated 2021 Aug 06; cited 2021 Aug 12]. Available from: https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvalsSearch in Google Scholar

19. United States District Court for the District of Delaware. Generic drugs Patent litigations; [updated 2021 Sep 25; cited 2021 Aug 02]. Available from: https://www.ded.uscourts.gov/Search in Google Scholar

20. Food and Drug Administration. Silver spring: orange book; [updated 2021 Aug 06; cited 2021 Aug 09]. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfmSearch in Google Scholar

21. Beall RF, Darrow JJ, Kesselheim AS. A method for approximating future entry of generic drugs. Value in Health. 2018;21(12):1382-9.10.1016/j.jval.2018.04.182730502781Search in Google Scholar

22. Lee Y, Fong EA. Patent lifecycle management strategies in open innovation projects. Drug Discovery Today. 2020;25(10):1782-5.10.1016/j.drudis.2020.06.01932592662Search in Google Scholar

23. Darrow JJ, Beall RF, Kesselheim AS. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Appl Health Econ Health Policy. 2019; 17(1):47-54.10.1007/s40258-018-0420-830141133Search in Google Scholar

24. Agranat I, Marom H. In Defense of Secondary Pharmaceutical Patents in Drug Discovery and Development. ACS Med Chem Lett. 2020; 11(2):91-98.10.1021/acsmedchemlett.9b00497710698532280427Search in Google Scholar

25. Socal MP, Parasrampuria S, Anderson GF. Modifying the Criteria for Granting Orphan Drug Market Exclusivity. Value Health. 2020; 23(11):1470-1476.10.1016/j.jval.2020.08.00433127018Search in Google Scholar

26. Kerr KW, Glos LJ. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases. Pharmaceut Med. 2020; 34(1):19-29.10.1007/s40290-019-00317-9Search in Google Scholar

27. Beall RF, Kesselheim AS, Sarpatwari A. New Drug Formulations and Their Respective Generic Entry Dates. J Manag Care Spec Pharm. 2019;25(2):218-224.10.18553/jmcp.2019.25.2.21830698097Search in Google Scholar

28. Fermont I. Pharmacovigilance strategy: opportunities for cross-national learning. Isr J Health Policy Res. 2019; 8(1):54.10.1186/s13584-019-0319-3658255731217025Search in Google Scholar

29. Bejarano A, Hewa Nadungodage C, Wang F, Catlin AC, Hoag SW. Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing. AAPS PharmSciTech. 2019; 20(6):223.10.1208/s12249-019-1440-x31214878Search in Google Scholar

30. Leistner A, Haerling S, Kreher JD, Becker I, Jung D, Holzgrabe U. Risk assessment report of potential impurities in cetirizine dihydrochloride. J Pharm Biomed Anal. 2020; 189:113425.10.1016/j.jpba.2020.11342532599488Search in Google Scholar

31. Ermer J, Aguiar D, Boden A, Ding B, Obeng D, Rose M, Vokrot J. Lifecycle management in pharmaceutical analysis: How to establish an efficient and relevant continued performance monitoring program. J Pharm Biomed Anal. 2020; 181:113051.10.1016/j.jpba.2019.11305131962246Search in Google Scholar

32. Charoo NA. Converging Generic Drug Product Development: Bioequivalence Design and Reference Product Selection. Clin Pharmacokinet. 2020; 59(11):1335-1355.10.1007/s40262-020-00912-z32757104Search in Google Scholar

33. Zhao L, Kim MJ, Zhang L, Lionberger R. Generating Model Integrated Evidence for Generic Drug Development and Assessment. Clin Pharmacol Ther. 2019; 105(2):338-349.10.1002/cpt.128230414386Search in Google Scholar

34. Rattan AK. Data Integrity: History, Issues, and Remediation of Issues. PDA J Pharm Sci Technol. 2018; 72(2):105-116.10.5731/pdajpst.2017.00776529158286Search in Google Scholar

35. Fermaglich LJ, Chen R, Kim CY, Chuh EE, Thomas T, Shetty D, Lee J, Young J, Fan Y. Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies. Ther Innov Regul Sci. 2019; 53(1):81-85.10.1177/216847901876929829719976Search in Google Scholar

36. Kugener VF, Freedland ES, Maynard KI, Aimer O, Webster PS, Salas M, Gossell-Williams M. Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. Drug Safety. 2021;1-0.10.1007/s40264-021-01078-8812309933993430Search in Google Scholar

37. Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020; 19(11):1505-1511.10.1080/14740338.2020.179997532693646Search in Google Scholar

38. Wittayanukorn S, Rosenberg M, Schick A, Hu M, Wang Z, Babiskin A, Lionberger R, Zhao L. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Ther Innov Regul Sci. 2020; 54(6):1372-1381.10.1007/s43441-020-00163-x32495310Search in Google Scholar